Compare ADMA Biologics Inc (ADMA) vs Delta Air Lines, Inc. (DAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Delta Air Lines, Inc. — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Delta Air Lines, Inc. trades at $87.2 (market cap $58.23B). The key difference: Delta Air Lines, Inc. is far larger — about 27.3× ADMA Biologics Inc's market cap, and Delta Air Lines, Inc. pays a 0.88% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | DAL | |
|---|---|---|
Market Cap | $2.13B | $58.23B |
Sector | Health | Industrials |
52-Week High | $20.38 | $93.66 |
52-Week Low | $7.60 | $50.52 |
Enterprise Value | $2.20B | $73.48B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Delta Air Lines (DAL) trades at $88.63, down 4.44% today, but maintains strong fundamentals with consistent earnings beats and improving cash flow. The stock shows bullish technical signals with moving averages supporting upward momentum, while trading near key support at $88. Analysts remain overwhelmingly positive with 81% buy ratings and a $105.36 consensus target, representing 19% upside potential from current levels.
DAL presents a compelling investment case with attractive valuation multiples (P/E 13.38, P/S 0.92) and robust profitability (ROE 24.99%). However, investors face risks from fuel price volatility, labor cost pressures, and cyclical industry exposure. The upcoming Q2 earnings report on July 10 will be critical for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →
